(Q38260301)

1 September 2017

1 reference

title

Primary debulking surgery for advanced ovarian cancer: are you a believer or a dissenter? (English)

1 reference

1 September 2017

1 reference

John O Schorge

1

1 reference

1 September 2017

Rachel M Clark

series ordinal

2

1 reference

1 September 2017

Susanna I Lee

series ordinal

3

1 reference

1 September 2017

Richard T Penson

series ordinal

4

1 reference

1 September 2017

language of work or name

English

0 references

publication date

12 October 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

135

1 reference

1 September 2017

issue

3

1 reference

1 September 2017

page(s)

595-605

1 reference

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

SGO White Paper on ovarian cancer: etiology, screening and surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Effect of Screening on Ovarian Cancer Mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal sarcomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

A critique of surgical cytoreduction in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Tumour stem cells and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The value of postoperative/preadjuvant chemotherapy computed tomography in the management of patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Neoadjuvant chemotherapy in advanced ovarian cancer: On what do we agree and disagree?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Neoadjuvant chemotherapy for advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Secondary surgical cytoreduction for advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: Survey results from members of the Society of Gynecologic Oncologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Primary surgery or neoadjuvant chemotherapy in ovarian cancer: what is the value of comparing apples with oranges?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Thirty-day mortality after primary cytoreductive surgery for advanced ovarian cancer in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Defining the limits of radical cytoreductive surgery for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The impact of body weight on ovarian cancer outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Height, weight, BMI and ovarian cancer survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Obesity and ovarian cancer survival: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

What is the optimal treatment for obese patients with advanced ovarian carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Impact of obesity on surgical and oncologic outcomes in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Effect of obesity on survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The effect of obesity on survival in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Racial disparities in the treatment of advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Analysis of factors impacting operability in stage IV ovarian cancer: rationale use of a triage system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Staging classification for cancer of the ovary, fallopian tube, and peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

(18)F-FDG-PET/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Preoperative 18F-FDG PET/CT in the management of advanced epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

ACR appropriateness criteria staging and follow-up of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Ovarian carcinomatosis: how the radiologist can help plan the surgical approach.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

External validation of a laparoscopic-based score to evaluate resectability of advanced ovarian cancers: clues for a simplified score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

A Laparoscopy-Based Score To Predict Surgical Outcome in Patients With Advanced Ovarian Carcinoma: A Pilot Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single-institution experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

A multicentric trial (Olympia-MITO 13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Prognostic significance of splenectomy as part of initial cytoreductive surgery in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.10.007

10.1016/J.YGYNO.2014.10.007

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference